Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies

Last updated: April 8, 2024
Sponsor: University of Sao Paulo General Hospital
Overall Status: Completed

Phase

N/A

Condition

Heart Defect

Heart Disease

Arrhythmia

Treatment

Dental restorative procedure

Clinical Study ID

NCT03182777
Odonto-Canalopatias
  • Ages > 6
  • All Genders

Study Summary

Patients with cardiac channelopathies needing restorative dental treatment will be included in two sessions of the study, using local dental anesthetic: lidocaine 2% with epinephrine and lidocaine 2% without vasoconstrictor. The safety of the use of two cartridges (3.6 mL) will be evaluated. The patients will be their own control and will be assessed by Holter monitoring for 28 hours, blood pressure measurement and anxiety measuring.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with any channelopathies below, kept on optimal drug therapy, with or withoutICD: Brugada Syndrome, Long QT Syndrome and Catecholaminergic Polymorphic VentricularTachycardia
  • Dental caries or unsatisfactory restorations in the mandible, indicating restorativedental treatment

Exclusion

Exclusion Criteria:

  • Patients allergic to lidocaine
  • Patients undergoing ICD therapy for less than three months
  • Patients with recurrent syncope in the last three months
  • Patients with sustained arrhythmias documented for less than 3 months
  • Have received epinephrine in the last 24 hours

Study Design

Total Participants: 31
Treatment Group(s): 1
Primary Treatment: Dental restorative procedure
Phase:
Study Start date:
May 01, 2015
Estimated Completion Date:
August 31, 2018

Study Description

Patients of Heart Institute of the University of São Paulo with inherited cardiac channelopathies will be included, considering the criteria for inclusion and non-inclusion, after reading and signing the informed consent.

They will undergo dental restorative treatment in two sessions, in the morning period, with an interval of at least seven days (wash-out) between them, and the patients will be their own control.

In the first session, after randomization, patients will receive lidocaine 2% without vasoconstrictor (LSA) or lidocaine 2% with 1: 100,000 epinephrine (LCA) (cross-over), resulting in two conditions: with adrenaline and without adrenaline.

The randomization of the anesthetic solution will be performed by the main researcher, being blind to the performer researcher and to the patient.

The injected volume will be 3.6 mL (2 cartridges) of the anesthetic solution, using blocking technique of the inferior alveolar nerve.

The patients will be monitored by Holter for 28 hours starting one hour before the procedure, for registration and analysis of cardiac electrical activity during the two sessions. Blood pressure will be monitored with digital sphygmomanometer and anxiety will be measured with Facial Image Scale, both on three occasions: at the beginning of the baseline periods, before starting application of anesthesia and at the end of the proceedings. The results will be analyzed statistically.

Connect with a study center

  • Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

    São Paulo, 05403000
    Brazil

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.